Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Immunovant Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.64 (market cap $12.58B), while Immunovant Inc. Common Stock trades at $30.18 (market cap $6.25B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2× Immunovant Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Immunovant Inc. Common Stock for 0 Days on average.
| HALO | IMVT | |
|---|---|---|
Market Cap | $12.58B | $6.25B |
Volume | 2,179,278 | 1,755,411 |
Sector | Health | Health |
52-Week High | $115.22 | $44.96 |
52-Week Low | $61.63 | $17.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.49B | $5.35B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
